HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Geographic Atrophy

A form of MACULAR DEGENERATION also known as dry macular degeneration marked by occurrence of a well-defined progressive lesion or atrophy in the central part of the RETINA called the MACULA LUTEA. It is distinguishable from WET MACULAR DEGENERATION in that the latter involves neovascular exudates.
Also Known As:
Dry Macular Degeneration; Atrophies, Geographic; Atrophy, Geographic; Degeneration, Dry Macular; Degenerations, Dry Macular; Dry Macular Degenerations; Geographic Atrophies; Macular Degeneration, Dry; Macular Degenerations, Dry
Networked: 226 relevant articles (7 outcomes, 28 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Macular Degeneration (Age-Related Maculopathy)
2. Choroidal Neovascularization
3. Cataract (Cataracts)
4. Eye Diseases (Eye Disease)
5. Cicatrix (Scar)

Experts

1. Klein, Ronald: 20 articles (04/2014 - 10/2002)
2. Klein, Barbara E K: 12 articles (12/2012 - 10/2002)
3. Holz, Frank G: 11 articles (12/2015 - 02/2002)
4. Ferris, Frederick L: 11 articles (09/2015 - 04/2005)
5. Schmitz-Valckenberg, Steffen: 9 articles (12/2015 - 02/2002)
6. Chew, Emily Y: 9 articles (09/2015 - 09/2007)
7. Ambati, Jayakrishna: 9 articles (11/2014 - 05/2003)
8. Hinton, David R: 8 articles (01/2015 - 10/2008)
9. Schmidt-Erfurth, Ursula: 7 articles (12/2015 - 04/2010)
10. Hirano, Yoshio: 7 articles (11/2014 - 03/2011)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Geographic Atrophy:
1. Retinaldehyde (Retinal)IBA
2. FenretinideIBA
3. Vitamin A (Retinol)FDA LinkGeneric
4. Carrier Proteins (Binding Protein)IBA
5. Ginkgo biloba extract 761 (Rokan)IBA
6. tandospironeIBA
7. Hydroxylamine (Hydroxylamine Hydrochloride)IBA
8. Genetic Markers (Genetic Marker)IBA
9. OT-551IBA
10. Complement Factor D (Factor D)IBA

Therapies and Procedures

1. Light Coagulation
01/01/2015 - "Only two studies investigated the effect on the development of geographic atrophy and could not show a difference, but estimates were imprecise (OR 1.30, 95% CI 0.38 to 4.51, two studies, 148 participants (148 eyes), low quality evidence).Among secondary outcomes, photocoagulation led to drusen reduction (OR 9.16, 95% CI 6.28 to 13.4, three studies, 570 participants (944 eyes), high quality evidence) but was not shown to limit loss of 3 or more lines of visual acuity (OR 0.99, 95% CI 0.81 to 1.22, nine studies, 2002 participants (2386 eyes), moderate quality evidence).In a subgroup analysis, no difference could be shown for conventional visible (eight studies) versus subthreshold invisible (four studies) photocoagulation for the primary outcomes (P value = 0.29). "
09/01/2008 - "Exclusion criteria included CNV and geographic atrophy >1 Macular Photocoagulation Study (MPS) disc area or within 500 micro of the foveal center. "
11/01/2005 - "Advanced AMD was defined as presence of 1 or more neovascular AMD abnormalities, photocoagulation for AMD, or geographic atrophy involving the center of the macula. "
01/01/2015 - " has been observed clinically that laser photocoagulation of drusen leads to their disappearance and may prevent the occurrence of advanced disease (CNV or geographic atrophy) associated with visual loss. "
01/01/2009 - " has been observed clinically that laser photocoagulation of drusen leads to their disappearance and may prevent the occurrence of advanced disease (CNV or geographic atrophy) associated with visual loss. "
2. Therapeutics
3. Electric Stimulation Therapy (Electrotherapy)
4. Lasers (Laser)
5. Injections